{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:51:13Z","timestamp":1761497473330,"version":"build-2065373602"},"reference-count":109,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.beem.2010.10.019","type":"journal-article","created":{"date-parts":[[2011,6,19]],"date-time":"2011-06-19T16:27:00Z","timestamp":1308500820000},"page":"415-427","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Disorders of fat partitioning in treated HIV\u2013infection"],"prefix":"10.1016","volume":"25","author":[{"given":"Esteban","family":"Mart\u00ednez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.beem.2010.10.019_bib1","doi-asserted-by":"crossref","first-page":"F51","DOI":"10.1097\/00002030-199807000-00003","article-title":"A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors","volume":"12","author":"Carr","year":"1998","journal-title":"AIDS"},{"key":"10.1016\/j.beem.2010.10.019_bib2","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1056\/NEJM199803263381301","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection","volume":"338","author":"Palella","year":"1998","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beem.2010.10.019_bib3","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/S0140-6736(99)06102-4","article-title":"Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy","volume":"354","author":"Brinkman","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2010.10.019_bib4","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/S0140-6736(00)04056-3","article-title":"Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study","volume":"357","author":"Martinez","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2010.10.019_bib5","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1097\/00126334-200301010-00007","article-title":"Incidence of and risk factors for lipoatrophy (abnormal fat loss) in ambulatory HIV-1-infected patients","volume":"32","author":"Lichtenstein","year":"2003","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.beem.2010.10.019_bib6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1089\/apc.2009.0191","article-title":"Prevalence and impact of body physical changes in HIV patients treated with highly active antiretroviral therapy: results from a study on patient and physician perceptions","volume":"24","author":"Cabrero","year":"2010","journal-title":"AIDS Patient Care STDs"},{"key":"10.1016\/j.beem.2010.10.019_bib7","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1089\/aid.2008.0264","article-title":"How much fat loss is needed for lipoatrophy to become clinically evident?","volume":"25","author":"Podzamczer","year":"2009","journal-title":"AIDS Research and Human Retroviruses"},{"key":"10.1016\/j.beem.2010.10.019_bib8","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00002030-200001070-00005","article-title":"Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study","volume":"14","author":"Saint-Marc","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.beem.2010.10.019_bib9","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2337\/diabetes.49.6.883","article-title":"The perils of portliness: causes and consequences of visceral adiposity","volume":"49","author":"Montague","year":"2000","journal-title":"Diabetes"},{"key":"10.1016\/j.beem.2010.10.019_bib10","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/01.qai.0000182230.47819.aa","article-title":"Fat distribution in men with HIV infection","volume":"40","author":"Bacchetti","year":"2005","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.beem.2010.10.019_bib11","doi-asserted-by":"crossref","first-page":"F25","DOI":"10.1097\/00002030-200002180-00001","article-title":"A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lypodystrophy syndrome","volume":"14","author":"Carr","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.beem.2010.10.019_bib12","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1161\/01.CIR.100.7.700","article-title":"Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study","volume":"100","author":"Periard","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.beem.2010.10.019_bib13","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1097\/00002030-200305020-00005","article-title":"Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy","volume":"17","author":"Mallon","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.beem.2010.10.019_bib14","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1001\/archinte.162.22.2621","article-title":"Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LipoICoNa Study","volume":"162","author":"Galli","year":"2002","journal-title":"Archives of Internal Medicine"},{"key":"10.1016\/j.beem.2010.10.019_bib15","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1046\/j.1464-2662.2001.00100.x","article-title":"Risk factors for the HIV-associated lipodystrophy syndrome in a closed cohort of patients after 3 years of antiretroviral treatment","volume":"3","author":"Mauss","year":"2002","journal-title":"HIV Medicine"},{"key":"10.1016\/j.beem.2010.10.019_bib16","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1111\/j.1468-1293.2007.00537.x","article-title":"Lipodystrophy and weight changes: data from the Swiss HIV Cohort Study, 2000\u20132006","volume":"9","author":"Nguyen","year":"2008","journal-title":"HIV Medicine"},{"key":"10.1016\/j.beem.2010.10.019_bib17","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/QAI.0b013e31802bf122","article-title":"Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study","volume":"44","author":"Podzamczer","year":"2007","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.beem.2010.10.019_bib18","unstructured":"Valantin MA, Flandre P, Kohtla S. et\u00a0al. Fat tissue distribution changes in HIV-infected patients with viral suppression treated with CDRV\/r monotherapy vs 2 NRTI + DRV\/r in the MONOI\u2013ANRS 136 randomized trial: results at 48 weeks. 17th Conference on retrovirus and Opportunistic Infections Feb 16\u201319 2010 San Francisco; 2010 Abstract 721."},{"key":"10.1016\/j.beem.2010.10.019_bib19","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1016\/S0140-6736(98)03391-1","article-title":"Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance","volume":"351","author":"Carr","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2010.10.019_bib20","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1097\/QAD.0b013e32832b4377","article-title":"Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment","volume":"23","author":"Haubrich","year":"2009","journal-title":"AIDS"},{"key":"10.1016\/j.beem.2010.10.019_bib21","unstructured":"McComsey G, Rightmire R, Wirtz V. et\u00a0al. Body composition changes in ARV-naive subjects treated with atazanavir or atazanavir\/ritonavir-based once-daily HAART: 96-week CT and DEXA data. 11th European AIDS Conference; Madrid, Spain; 24\u201327 October 2007; 2007 Abstract P9.3\/04."},{"key":"10.1016\/j.beem.2010.10.019_bib22","unstructured":"Moyle G, Hu W, Yang R. et\u00a0al. Body composition changes in treatment-na\u00efve patients treated with boosted protease inhibitors plus tenofovir\/emtricitabine. Results from the Castle trial from 96 weeks. 12th European AIDS Conference November 11\u201314, 2009 Cologne, Germany 2009; Abstract LBPS11\/6."},{"key":"10.1016\/j.beem.2010.10.019_bib23","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial","volume":"292","author":"Gallant","year":"2004","journal-title":"JAMA: the Journal of the American Medical Association"},{"key":"10.1016\/j.beem.2010.10.019_bib24","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa051871","article-title":"Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV","volume":"354","author":"Gallant","year":"2006","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beem.2010.10.019_bib25","unstructured":"DeJesus E, Cohen C, Lennox J. et\u00a0al. Metabolic profiles and body composition changes in treatment-naive HIV-infected patients treated with raltegravir 400 mg twice-daily vs efavirenz 600 mg each bedtime combination therapy: 96-week follow-up. 17th Conference on Retrovirus and Opportunistic Infections Feb 16\u201319, 2010 San Francisco 2010; Abstract 720."},{"key":"10.1016\/j.beem.2010.10.019_bib26","unstructured":"Cooper DA, Cordery DV, Reiss P. et\u00a0al. The effects of enfuvirtide on body composition and metabolic parameters over 48 weeks in the TORO body imaging substudy. HIV Med (in press)."},{"key":"10.1016\/j.beem.2010.10.019_bib27","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0140-6736(97)11518-5","article-title":"Visceral abdominal-fat accumulation associated with use of indinavir","volume":"351","author":"Miller","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2010.10.019_bib28","first-page":"244","article-title":"Efavirenz-associated gynecomastia: report of five cases and review of the literature","volume":"10","author":"Jover","year":"2004","journal-title":"The\u00a0Breast Journal"},{"key":"10.1016\/j.beem.2010.10.019_bib29","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1086\/425363","article-title":"Gynecomastia among HIV-infected patients is associated with hypogonadism: a case-control study","volume":"39","author":"Biglia","year":"2004","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.beem.2010.10.019_bib30","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1177\/135965350400900206","article-title":"Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations","volume":"9","author":"Gougeon","year":"2004","journal-title":"Antiviral Therapy"},{"key":"10.1016\/j.beem.2010.10.019_bib31","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1086\/599986","article-title":"Gene expression and immunohistochemistry in adipose tissue of HIV type 1-infected patients with nucleoside analogue reverse-transcriptase inhibitor-associated lipoatrophy","volume":"200","author":"Sievers","year":"2009","journal-title":"The Journal of Infectious Diseases"},{"key":"10.1016\/j.beem.2010.10.019_bib32","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1128\/AAC.01449-07","article-title":"Mitochondrial DNA content, an inaccurate biomarker of mitochondrial alteration in human immunodeficiency virus-related lipodystrophy","volume":"52","author":"Kim","year":"2008","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/j.beem.2010.10.019_bib33","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1161\/01.ATV.0000034707.40046.02","article-title":"HIV protease inhibitor ritonavir induces cytotoxicity of human endothelial cells","volume":"22","author":"Zhong","year":"2002","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"10.1016\/j.beem.2010.10.019_bib34","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.molmed.2010.03.002","article-title":"HIV-associated lipodystrophy: from fat injury to premature aging","volume":"16","author":"Caron-Debarle","year":"2010","journal-title":"Trends in Molecular Medicine"},{"key":"10.1016\/j.beem.2010.10.019_bib35","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.bbabio.2004.03.013","article-title":"Bioenergetics of mitochondrial diseases associated with mtDNA mutations","volume":"1658","author":"Lenaz","year":"2004","journal-title":"Biochimica et Biophysica Acta"},{"key":"10.1016\/j.beem.2010.10.019_bib36","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0009-9120(01)00239-9","article-title":"Sterol regulatory element-binding proteins and reactive oxygen species: potential role in highly-active antiretroviral therapy (HAART)-associated lipodystrophy","volume":"34","author":"Nerurkar","year":"2001","journal-title":"Clinical Biochemistry"},{"key":"10.1016\/j.beem.2010.10.019_bib37","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1177\/135965350300800409","article-title":"Mitochondrial proliferation, DNA depletion and adipocyte differentiation in subcutaneous adipose tissue of HIV-positive HAART recipients","volume":"8","author":"Pace","year":"2003","journal-title":"Antiviral Therapy"},{"key":"10.1016\/j.beem.2010.10.019_bib38","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0014-5793(03)00862-7","article-title":"Inhibition of preadipocyte proliferation by mitochondrial reactive oxygen species","volume":"550","author":"Carriere","year":"2003","journal-title":"FEBS Letters"},{"key":"10.1016\/j.beem.2010.10.019_bib39","doi-asserted-by":"crossref","first-page":"40462","DOI":"10.1074\/jbc.M407258200","article-title":"Mitochondrial reactive oxygen species control the transcription factor CHOP-10\/GADD153 and adipocyte differentiation: a mechanism for hypoxia-dependent effect","volume":"279","author":"Carriere","year":"2004","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.beem.2010.10.019_bib40","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0165-6147(03)00125-1","article-title":"Mitochondrion-mediated apoptosis in HIV-1 infection","volume":"24","author":"Badley","year":"2003","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.beem.2010.10.019_bib41","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.tips.2004.12.005","article-title":"Lipodystrophy associated with highly active anti-retroviral therapy for HIV infection: the adipocyte as a target of anti-retroviral-induced mitochondrial toxicity","volume":"26","author":"Villarroya","year":"2005","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.beem.2010.10.019_bib42","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1177\/135965350601100610","article-title":"HIV-1 infection alters gene expression in adipose tissue, which contributes to HIV- 1\/HAART-associated lipodystrophy","volume":"11","author":"Giralt","year":"2006","journal-title":"Antiviral Therapy"},{"key":"10.1016\/j.beem.2010.10.019_bib43","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1097\/00002030-200409240-00013","article-title":"Adipose tissue expression of IL-18 and HIV-associated lipodystrophy","volume":"18","author":"Lindegaard","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.beem.2010.10.019_bib44","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1177\/135965350400900412","article-title":"Altered fat differentiation and adipocytokine expression are inter-related and linked to morphological changes and insulin resistance in HIV-1-infected lipodystrophic patients","volume":"9","author":"Jan","year":"2004","journal-title":"Antiviral Therapy"},{"key":"10.1016\/j.beem.2010.10.019_bib45","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/S0140-6736(02)08094-7","article-title":"Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal adipocyte differentiation and insulin resistance","volume":"359","author":"Bastard","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2010.10.019_bib46","doi-asserted-by":"crossref","first-page":"E85","DOI":"10.1152\/ajpendo.90224.2008","article-title":"Adipose tissue inflammation and liver fat in patients with highly active antiretroviral therapy-associated lipodystrophy","volume":"295","author":"Sevastianova","year":"2008","journal-title":"American Journal of Physiology. Endocrinology and Metabolism"},{"key":"10.1016\/j.beem.2010.10.019_bib47","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1097\/QAD.0b013e3282f56b40","article-title":"Differential gene expression indicates that \u2019buffalo hump\u2019 is a distinct adipose tissue disturbance in HIV-1-associated lipodystrophy","volume":"22","author":"Guallar","year":"2008","journal-title":"AIDS"},{"issue":"Suppl. 4","key":"10.1016\/j.beem.2010.10.019_bib48","first-page":"A25","article-title":"Genome-wide transcriptomic an\u00e1lisis reveals distinct patterns of altered gene expression in subcutaneous adipose tissue associated with HIV-1 infection, antiretroviral treatment and lipodystrophy","volume":"13","author":"Domingo","year":"2008","journal-title":"Antiviral Therapy"},{"key":"10.1016\/j.beem.2010.10.019_bib49","doi-asserted-by":"crossref","first-page":"6770","DOI":"10.1074\/jbc.274.10.6770","article-title":"Tumor necrosis factor alpha stimulates lipolysis in adipocytes by decreasing Gi protein concentrations","volume":"274","author":"Gasic","year":"1999","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.beem.2010.10.019_bib50","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1177\/135965350701200809","article-title":"A 6-month interruption of antiretroviral therapy improves adipose tissue function in HIV-infected patients: the ANRS EP29 Lipostop Study","volume":"12","author":"Kim","year":"2007","journal-title":"Antiviral Therapy"},{"key":"10.1016\/j.beem.2010.10.019_bib51","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1177\/135965350701200601","article-title":"Altered expression of nucleoside transporter genes (SLC28 and SLC29) in adipose tissue from HIV-1-infected patients","volume":"12","author":"Guallar","year":"2007","journal-title":"Antiviral Therapy"},{"key":"10.1016\/j.beem.2010.10.019_bib52","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3851\/IMP1296","article-title":"Combined effect of C-reactive protein and stavudine on adipogenesis","volume":"14","author":"Stankov","year":"2009","journal-title":"Antiviral Therapy"},{"key":"10.1016\/j.beem.2010.10.019_bib53","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.2174\/138161207781039599","article-title":"Visceral and subcutaneous adiposity: are both potential therapeutic targets for tackling the metabolic syndrome?","volume":"13","author":"Rodriguez","year":"2007","journal-title":"Current Pharmaceutical Design"},{"key":"10.1016\/j.beem.2010.10.019_bib54","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/S0165-6147(03)00132-9","article-title":"Do regional differences in adipocyte biology provide new pathophysiological insights?","volume":"24","author":"Lafontan","year":"2003","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.beem.2010.10.019_bib55","doi-asserted-by":"crossref","first-page":"E315","DOI":"10.1152\/ajpendo.90486.2008","article-title":"Depot-specific adipocyte cell lines reveal differential drug-induced responses of white adipocytes \u2013 relevance for partial lipodystrophy","volume":"296","author":"Kovsan","year":"2009","journal-title":"American Journal of Physiology. Endocrinology and Metabolism"},{"key":"10.1016\/j.beem.2010.10.019_bib56","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.bcp.2005.04.015","article-title":"Site specific alterations of adipose tissue mitochondria in 3\u2032-azido-3\u2032-deoxythymidine (AZT)-treated rats: an early stage in lipodystrophy?","volume":"70","author":"Deveaud","year":"2005","journal-title":"Biochemical Pharmacology"},{"issue":"Suppl. 4","key":"10.1016\/j.beem.2010.10.019_bib57","first-page":"A15","article-title":"Differential alterations of gene expression in visceral versus subcutaneous adipose tissue from HIV-1-infected, HAART-treated patients with lipodystrophy: a pilot study","volume":"13","author":"Villarroya","year":"2010","journal-title":"Antiviral Therapy"},{"key":"10.1016\/j.beem.2010.10.019_bib58","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S0140-6736(97)11443-X","article-title":"\u201cBuffalo hump\u201d in men with HIV-1 infection","volume":"351","author":"Lo","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.beem.2010.10.019_bib59","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1097\/01.qai.0000147527.64863.1a","article-title":"Buffalo hump seen in HIV-associated lipodystrophy is associated with hyperinsulinemia but not dyslipidemia","volume":"38","author":"Mallon","year":"2005","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.beem.2010.10.019_bib60","first-page":"25","article-title":"Ultrastructural findings consistent with brown adipocytes in buffalo humps of HIV-positive patients with fat redistribution syndrome","volume":"5","author":"Fessel","year":"2000","journal-title":"Antiviral Therapy"},{"key":"10.1016\/j.beem.2010.10.019_bib61","first-page":"417","article-title":"The importance of brown adipose tissue","volume":"361","author":"Villarroya","year":"2009","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beem.2010.10.019_bib62","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1152\/physrev.00015.2003","article-title":"Brown adipose tissue: function and physiological significance","volume":"84","author":"Cannon","year":"2004","journal-title":"Physiological Reviews"},{"key":"10.1016\/j.beem.2010.10.019_bib63","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1177\/135965350501000407","article-title":"Reverse transcriptase inhibitors alter uncoupling protein-1 and mitochondrial biogenesis in brown adipocytes","volume":"10","author":"Rodriguez de la Concepcion","year":"2005","journal-title":"Antiviral Therapy"},{"year":"2009","series-title":"European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults in Europe","author":"Clumeck","key":"10.1016\/j.beem.2010.10.019_bib64"},{"issue":"6","key":"10.1016\/j.beem.2010.10.019_bib65","first-page":"362","article-title":"Panel de expertos de Gesida y Plan Nacional sobre el Sida. Documento de consenso de Gesida\/Plan Nacional sobre el SIDA respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana: actualizaci\u00f3n enero 2010","volume":"28","year":"2010","journal-title":"Enfermedades infecciosas y microbiolog\u00eda cl\u00ednica"},{"key":"10.1016\/j.beem.2010.10.019_bib66","unstructured":"McComsey G, Kitch D, Daar E. et\u00a0al. Bone and limb fat outcomes of ACTG A5224s, a substudy of ACTG A5202: a prospective, randomized, partially blinded phase III trial of ABC\/3TC or TDF\/FTC with EFV or ATV\/r for initial treatment of HIV-1 infection. 17th Conference on Retrovirus and Opportunistic Infections Feb 16\u201319, 2010 San Francisco 2010; Abstract 106LB."},{"key":"10.1016\/j.beem.2010.10.019_bib67","unstructured":"Mocroft A, Reiss P, Gasiorowski P. et\u00a0al. Serious fatal and non-fatal non-AIDS-defining illnesses in Europe. 16th Conference on Retroviruses and Opportunistic Infections Montreal, Canada 2009; Abstract 707."},{"key":"10.1016\/j.beem.2010.10.019_bib68","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/01.qai.0000167478.28051.3a","article-title":"Redefining lipodystrophy syndrome: risks and impact on clinical decision making","volume":"39","author":"Lichtenstein","year":"2005","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.beem.2010.10.019_bib69","first-page":"215","article-title":"IL-1beta (+3954C\/T) polymorphism could protect human immunodeficiency virus (HIV)-infected patients on highly active antiretroviral treatment (HAART) against lipodystrophic syndrome","volume":"10","author":"Asensi","year":"2008","journal-title":"Genetics in\u00a0Medicine"},{"key":"10.1016\/j.beem.2010.10.019_bib70","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1097\/QAD.0b013e32830a9886","article-title":"Genetic analysis implicates resistin in HIV lipodystrophy","volume":"22","author":"Ranade","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.beem.2010.10.019_bib71","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1097\/QAD.0b013e32830b3a96","article-title":"Genetic polymorphisms differently influencing the emergence of atrophy and fat accumulation in HIV-related lipodystrophy","volume":"22","author":"Zanone","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.beem.2010.10.019_bib72","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1177\/135965350801300208","article-title":"Use of diet, nutritional supplements and exercise in HIV-infected patients receiving combination antiretroviral therapies: a systematic review","volume":"13","author":"Leyes","year":"2008","journal-title":"Antiviral Therapy"},{"issue":"Suppl. 2","key":"10.1016\/j.beem.2010.10.019_bib73","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1086\/375887","article-title":"Dietary habits and their association with metabolic abnormalities in human immunodeficiency virus-related lipodystrophy","volume":"37","author":"Hadigan","year":"2003","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.beem.2010.10.019_bib74","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1468-1293.2008.00579.x","article-title":"Adrenal suppression and Cushing\u2019s syndrome secondary to an interaction between ritonavir and fluticasone: a review of the literature","volume":"9","author":"Foisy","year":"2008","journal-title":"HIV Medicine"},{"key":"10.1016\/j.beem.2010.10.019_bib75","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/01.qai.0000229996.75116.da","article-title":"Study of fat redistribution and metabolic change in HIV infection (FRAM). Fat distribution in women with HIV infection","volume":"42","year":"2006","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.beem.2010.10.019_bib76","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1097\/QAD.0b013e32833ac7a2","article-title":"Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy","volume":"24","author":"Grunfeld","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.beem.2010.10.019_bib77","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1139\/h05-117","article-title":"Effects of different types of exercise on body composition and fat distribution in HIV-infected patients: a brief review","volume":"30","author":"Malita","year":"2005","journal-title":"Canadian Journal of Applied Physiology"},{"key":"10.1016\/j.beem.2010.10.019_bib78","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1086\/343050","article-title":"Switching effective antiretroviral therapy: a review","volume":"35","author":"Drechsler","year":"2002","journal-title":"Clinical Infectious Diseases"},{"key":"10.1016\/j.beem.2010.10.019_bib79","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1080\/00365540410019381","article-title":"Impact of switching antiretroviral therapy on lipodystrophy and other metabolic complications: a review","volume":"36","author":"Hansen","year":"2004","journal-title":"Scandinavian Journal of Infectious Diseases"},{"key":"10.1016\/j.beem.2010.10.019_bib80","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00126334-200305010-00005","article-title":"Randomized, controlled, 48-week study of switching stavudine and\/or protease inhibitors to combivir\/abacavir to prevent or reverse lipoatrophy in HIV-infected patients","volume":"33","author":"John","year":"2003","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.beem.2010.10.019_bib81","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1177\/135965350701200301","article-title":"The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients","volume":"12","author":"Milinkovic","year":"2007","journal-title":"Antiviral Therapy"},{"key":"10.1016\/j.beem.2010.10.019_bib82","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/QAD.0b013e3283333666","article-title":"The effects of intermittent, CD4-guided antiretroviral therapy on body composition and metabolic parameters","volume":"24","author":"Martinez","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.beem.2010.10.019_bib83","first-page":"A9","article-title":"Greater limb fat increase with intermittent (relative to continuous) thymidine-sparing antiretroviral therapy in HIV-infected patients with lipoatrophy","volume":"13","author":"Martinez","year":"2008","journal-title":"Antiviral Therapy"},{"key":"10.1016\/j.beem.2010.10.019_bib84","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1001\/jama.288.2.207","article-title":"Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial","volume":"288","author":"Carr","year":"2002","journal-title":"JAMA: the Journal of the American Medical Association"},{"key":"10.1016\/j.beem.2010.10.019_bib85","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1097\/QAI.0b013e318042e204","article-title":"Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir\/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s)","volume":"45","author":"Tebas","year":"2007","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.beem.2010.10.019_bib86","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1097\/QAI.0b013e3181ae2eb9","article-title":"A randomized comparative trial of continued zidovudine\/lamivudine or replacement with tenofovir disoproxil fumarate\/emtricitabine in efavirenz-treated HIV-1-infected individuals","volume":"51","author":"Fisher","year":"2009","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.beem.2010.10.019_bib87","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/00002030-200404300-00011","article-title":"Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOX Extension Study","volume":"18","author":"Martin","year":"2004","journal-title":"AIDS"},{"key":"10.1016\/j.beem.2010.10.019_bib88","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1056\/NEJMra041001","article-title":"Thiazolidinediones","volume":"351","author":"Yki-Jarvinen","year":"2004","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beem.2010.10.019_bib89","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1310\/hct1101-39","article-title":"A meta-analysis of six placebo-controlled trials of thiazolidinedione therapy for HIV lipoatrophy","volume":"11","author":"Raboud","year":"2010","journal-title":"HIV Clinical Trials"},{"key":"10.1016\/j.beem.2010.10.019_bib90","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/1471-2334-10-183","article-title":"The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials","volume":"10","author":"Sheth","year":"2010","journal-title":"BMC Infectious Diseases"},{"key":"10.1016\/j.beem.2010.10.019_bib91","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1086\/593179","article-title":"Effect of rosiglitazone on peroxisome proliferator-activated receptor gamma gene expression in human adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunction","volume":"198","author":"Mallon","year":"2008","journal-title":"The Journal of Infectious Diseases"},{"key":"10.1016\/j.beem.2010.10.019_bib92","unstructured":"Slama L, Lavoy E, Valentin MA. et\u00a0al. Effect of pioglitazone on HIV-1 related lipoatrophy: a randomized double-blind placebo-controlled trial (ANRS 113) with 130 patients. 13th Conference on Retrovirus and Opportunistic Infection, Denver, February 5\u20138; 2006 Abstract 151LB."},{"key":"10.1016\/j.beem.2010.10.019_bib93","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1097\/QAD.0b013e328339e274","article-title":"Rosiglitazone improves lipoatrophy in patients receiving thymidine-sparing regimens","volume":"24","author":"Tungsiripat","year":"2010","journal-title":"AIDS"},{"key":"10.1016\/j.beem.2010.10.019_bib94","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1161\/CIR.0b013e3181d34114","article-title":"Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart association and American College of Cardiology Foundation","volume":"121","author":"Kaul","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.beem.2010.10.019_bib95","unstructured":"Guaraldi G, Fontdevilla J, Christensern LH. et\u00a0al. Surgical correction of HIV-associated facial lipoatrophy. AIDS (in press)."},{"key":"10.1016\/j.beem.2010.10.019_bib96","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.asj.2008.05.002","article-title":"Assessing the long-term viability of facial fat grafts: an objective measure using computed tomography","volume":"28","author":"Fontdevila","year":"2008","journal-title":"Aesthetic Surgery Journal"},{"key":"10.1016\/j.beem.2010.10.019_bib97","first-page":"3","article-title":"Epidemiology, assessment, and management of excess abdominal fat in persons with HIV infection","volume":"12","author":"Moyle","year":"2010","journal-title":"AIDS Reviews"},{"key":"10.1016\/j.beem.2010.10.019_bib98","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1210\/jc.2006-2060","article-title":"Effects of testosterone supplementation on whole body and regional fat mass and distribution in human immunodeficiency virus-infected men with abdominal obesity","volume":"92","author":"Bhasin","year":"2007","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.beem.2010.10.019_bib99","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1001\/jama.284.4.472","article-title":"Metformin in the treatment of HIV lipodystrophy syndrome: a randomized controlled trial","volume":"284","author":"Hadigan","year":"2000","journal-title":"JAMA: the Journal of the American Medical Association"},{"key":"10.1016\/j.beem.2010.10.019_bib100","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1468-1293.2007.00488.x","article-title":"A randomized placebo-controlled trial of metformin for the treatment of HIV lipodystrophy","volume":"8","author":"Kohli","year":"2007","journal-title":"HIV Medicine"},{"key":"10.1016\/j.beem.2010.10.019_bib101","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1177\/135965350300800507","article-title":"Effects of metformin or gemfibrozil on the lipodystrophy of HIV-infected patients receiving protease inhibitors","volume":"8","author":"Martinez","year":"2003","journal-title":"Antiviral Therapy"},{"key":"10.1016\/j.beem.2010.10.019_bib102","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1097\/QAD.0b013e328011220e","article-title":"Effects of metformin and rosiglitazone in HIV-infected patients with hyperinsulinemia and elevated waist\/hip ratio","volume":"21","author":"Mulligan","year":"2007","journal-title":"AIDS"},{"key":"10.1016\/j.beem.2010.10.019_bib103","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1093\/ajcn\/61.6.1290","article-title":"Adipose tissue assessed by magnetic resonance imaging in growth hormone-deficient adults: the effect of growth hormone replacement and a comparison with control subjects","volume":"61","author":"Snel","year":"1995","journal-title":"American Journal of Clinical Nutrition"},{"key":"10.1016\/j.beem.2010.10.019_bib104","first-page":"504","article-title":"Assessment of growth hormone dynamics in human immunodeficiency virus-related lipodystrophy","volume":"86","author":"Rietschel","year":"2001","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"key":"10.1016\/j.beem.2010.10.019_bib105","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1056\/NEJMoa072375","article-title":"Metabolic effects of a growth hormone-releasing factor in patients with HIV","volume":"357","author":"Falutz","year":"2007","journal-title":"The New England Journal of Medicine"},{"key":"10.1016\/j.beem.2010.10.019_bib106","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/QAI.0b013e3181cbdaff","article-title":"Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension","volume":"53","author":"Falutz","year":"2010","journal-title":"Journal of Acquired Immune Deficiency Syndromes"},{"key":"10.1016\/j.beem.2010.10.019_bib107","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1089\/apc.2005.19.353","article-title":"Reduction mammoplasty in an HIV-positive woman","volume":"19","author":"Johnson","year":"2005","journal-title":"AIDS Patient Care STDs"},{"key":"10.1016\/j.beem.2010.10.019_bib108","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/01.sap.0000248128.33465.83","article-title":"Surgical management of HIV-associated lipodystrophy: role of ultrasonic-assisted liposuction and suction-assisted lipectomy in the treatment of lipohypertrophy","volume":"58","author":"Hultman","year":"2007","journal-title":"Annals of Plastic Surgery"},{"key":"10.1016\/j.beem.2010.10.019_bib109","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.bjps.2007.11.014","article-title":"Plastic surgical options for HIV-associated lipodystrophy","volume":"61","author":"Nelson","year":"2008","journal-title":"Journal of Plastic, Reconstructive & Aesthetic Surgery"}],"container-title":["Best Practice & Research Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X10001466?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521690X10001466?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T16:45:10Z","timestamp":1761497110000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521690X10001466"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":109,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S1521690X10001466"],"URL":"https:\/\/doi.org\/10.1016\/j.beem.2010.10.019","relation":{},"ISSN":["1521-690X"],"issn-type":[{"type":"print","value":"1521-690X"}],"subject":[],"published":{"date-parts":[[2011,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Disorders of fat partitioning in treated HIV\u2013infection","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Endocrinology & Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beem.2010.10.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}